Ampersand Capital Partners said Monday that Eric Lev has joined as a partner, while Dana Niles was named CFO and Chief Compliance Officer. John Perkins also joined Ampersand as an operating partner. Lev was most recently at Water Street Healthcare Partners where he served on their investment team. Niles previously was CFO of HighPoint Capital. And Perkins was a senior executive at Talecris Biotherapeutics, an Ampersand portfolio company.
Ampersand Capital Partners, a healthcare-focused, middle market private equity firm, is pleased to announce three additions to its management team.
Eric Lev has joined Ampersand as a Partner, bringing over 12 years of middle market healthcare investing experience. Eric was most recently at Water Street Healthcare Partners where he served on the investment team since Water Street’s formation in 2005. While at Water Street, Eric played a key role in helping to build the firm’s practices in life sciences and diagnostics. Prior to Water Street, Eric worked at Beckman Coulter and at One Equity Partners. Eric holds a BA from Northwestern University and a MBA from the University of Chicago.
Dana Niles has joined Ampersand as the firm’s CFO and Chief Compliance Officer. Prior to Ampersand, Dana served as CFO of HighPoint Capital, a senior debt platform acquired by Crescent Capital in 2012. Before HighPoint, Dana served as Controller at both HLM Venture Partners and YankeeTek Ventures and as a Senior Auditor at Arthur Andersen. Dana holds a BS in Business Administration from the University of Vermont and is a CPA.
John Perkins has joined Ampersand as an Operating Partner, where he will work with the investment team to identify and evaluate new platform opportunities. Most recently, John served as a senior executive at Ampersand portfolio company Talecris Biotherapeutics, which was acquired by Grifols in 2011. Prior to Talecris, John held roles as an operating executive at Cerberus and as an executive at General Electric. John holds a BA from DePauw University and a MBA from the Kellogg School of Management.
“Ampersand has been making successful middle-market healthcare investments for twenty years, and these key additions further build on our strong base of healthcare investment experience and operating talent,” commented Herb Hooper , Ampersand Managing Partner. Over the last twenty years, Ampersand has invested in more than forty private healthcare companies; of these, the twenty-four realized investments have yielded a gross return multiple of more than 5X.
Ampersand is a Boston-based private equity firm with a focus on middle market growth equity investments in the Healthcare sector. Ampersand leverages its unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Over the past twenty years, Ampersand has raised seven funds, producing a 25% pooled internal rate of return to Limited Partners (net of all fees and carried interest). To learn more about Ampersand, visit www.ampersandcapital.com.